www.bioss.com.cn
sales@bioss.com.cn
techsupport@bioss.com.cn
400-901-9800

OSI-027

产品编号: D50783
CAS: 936890-98-1
分子式: C21H22N6O3
纯度: ≥98%
InChi: InChI=1S/C21H22N6O3/c1-30-15-4-2-3-13-9-14(25-16(13)15)17-18-19(22)23-10-24-27(18)20(26-17)11-5-7-12(8-6-11)21(28)29/h2-4,9-12,25H,5-8H2,1H3,(H,28,29)(H2,22,23,24)/t11-,12-
InChi Key: JROFGZPOBKIAEW-HAQNSBGRSA-N
Smiles: COC1C=CC=C2C=C(NC2=1)C1N=C([C@@H]2CC[C@H](CC2)C(O)=O)N2N=CN=C(N)C2=1
外观: 固体粉末
作用通路: Autophagy
溶解性: DMSO up to 50 mM
保存条件: Store in dry, dark place for one year.
产品介绍: OSI-027 is a selective and potent dual inhibitor of mTORC1 and mTORC2 with IC50 of 22 nM and 65 nM, respectively. It shows more than 100-fold selectivity for mTOR relative to PI3Kα, PI3Kβ, PI3Kγ, and DNA-PK. It inhibits phosphorylation of the mTORC1 substrates 4E-BP1 and S6K1 as well as the mTORC2 substrate AKT in diverse cancer models in vitro and in vivo. OSI-027 shows robust antitumor activity in several different human xenograft models representing various histologies. In COLO 205 and GEO colon cancer xenograft models, OSI-027 showed superior efficacy compared with rapamycin. OSI-027 is currently in Phase I clinical trials in patients with advanced solid tumors or lymphoma.